Tissue engineering and regenerative medicine in Asia-Pacific, the same but different
New Rochelle, NY, March 1, 2016–Regulation of the emerging areas of tissue engineering and regenerative medicine (TERM) is one of the key barriers to commercial and clinical success of TERM globally. Countries face many of the same regulatory challenges, but must address them in light of regional differences based on cultural, political, and economic factors, as examined in a Commentary published as part of a special issue of Tissue Engineering, Part A, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Tissue Engineering website until April 1, 2016.
David Williams, DSc, Wake Forest Institute of Regenerative Medicine, Winston-Salem, NC and Immediate Past-President, Tissue Engineering and Regenerative Medicine International Society (TERMIS), discusses the articles contributed by authors from several Asia-Pacific countries in the context of current trends in global regulation of TERM products and services. He emphasizes the need to find the right balance between risk and benefit, and risk and innovation. In the article "The Same but Different: Regulation of Tissue Engineering and Regenerative Medicine in the Context of Regional and International Standards and Expectations", Dr. Williams highlights the importance of regional differences in demographics and disease prevalence, and cultural differences related to the use of donated tissues and organs and xenogeneic materials.
"David Williams is uniquely suited to provide a balanced view of worldwide regulatory approaches to tissue engineering and regenerative medicine as a result of the significant international exposure he has had to the development and commercialization of such products," says Co-Editor-in-Chief Peter C. Johnson, MD, Prinicipal, MedSurgPI, LLC and President and CEO, Scintellix, LLC, Raleigh, NC
###
About the Journal
Tissue Engineering is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published bimonthly, and Part C: Methods, published 12 times per year. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Prinicipal, MedSurgPI, LLC and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed online at the Tissue Engineering website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy, and Advances in Wound Care. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Media Contact
Kathryn Ryan
[email protected]
914-740-2100
@LiebertPub
http://www.liebertpub.com
